Literature DB >> 24936590

Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.

Noton K Dutta1, Michael L Pinn1, Petros C Karakousis2.   

Abstract

We recently reported that in lung tissue, thioridazine accumulates at high concentrations relative to serum levels, displaying modest synergy with isoniazid and reducing the emergence of isoniazid-resistant mutants in mouse lungs. In this study, we sought to investigate the sterilizing activity of human-equivalent doses of thioridazine when given in combination with the "Denver regimen" against acute murine tuberculosis. We found a trend toward a positive impact of thioridazine on the bacterial clearance and lowering relapse rates of the combined standard TB chemotherapy.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24936590      PMCID: PMC4135856          DOI: 10.1128/AAC.03408-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  In vitro activity of thioridazine against mycobacteria.

Authors:  Jakko van Ingen; Tridia van der Laan; Leonard Amaral; Richard Dekhuijzen; Martin J Boeree; Dick van Soolingen
Journal:  Int J Antimicrob Agents       Date:  2009-04-05       Impact factor: 5.283

2.  Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine.

Authors:  Eduardo Abbate; Marisa Vescovo; Marcela Natiello; Mónica Cufré; Ana García; Pablo Gonzalez Montaner; Marta Ambroggi; Viviana Ritacco; Dick van Soolingen
Journal:  J Antimicrob Chemother       Date:  2011-12-01       Impact factor: 5.790

3.  Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.

Authors:  Noton K Dutta; Michael L Pinn; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

Review 4.  Latent tuberculosis: is there a role for thioridazine?

Authors:  Charles Sohaskey
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2011-05

5.  Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice.

Authors:  Noton K Dutta; Peter B Illei; Sanjay K Jain; Petros C Karakousis
Journal:  Am J Pathol       Date:  2014-05-09       Impact factor: 4.307

6.  The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis.

Authors:  Dick van Soolingen; Rogelio Hernandez-Pando; Hector Orozco; Diana Aguilar; Cecile Magis-Escurra; Leonard Amaral; Jakko van Ingen; Martin J Boeree
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

7.  Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration.

Authors:  Charles D Sohaskey
Journal:  J Bacteriol       Date:  2008-02-22       Impact factor: 3.490

8.  Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.

Authors:  J Dhillon; J M Dickinson; K Sole; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis.

Authors:  Noton K Dutta; Michael L Pinn; Ming Zhao; Michelle A Rudek; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2013-03-05       Impact factor: 5.790

10.  The role of transport mechanisms in mycobacterium tuberculosis drug resistance and tolerance.

Authors:  Jansy Passiflora Sarathy; Véronique Dartois; Edmund Jon Deoon Lee
Journal:  Pharmaceuticals (Basel)       Date:  2012-11-09
View more
  8 in total

1.  Statin adjunctive therapy shortens the duration of TB treatment in mice.

Authors:  Noton K Dutta; Natalie Bruiners; Michael L Pinn; Matthew D Zimmerman; Brendan Prideaux; Véronique Dartois; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2016-02-21       Impact factor: 5.790

2.  A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis.

Authors:  Virginia Meikle; Ann-Kristin Mossberg; Avishek Mitra; Anders P Hakansson; Michael Niederweis
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.

Authors:  Kohta Saito; Thulasi Warrier; Selin Somersan-Karakaya; Lina Kaminski; Jianjie Mi; Xiuju Jiang; Suna Park; Kristi Shigyo; Ben Gold; Julia Roberts; Elaina Weber; William R Jacobs; Carl F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

4.  Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.

Authors:  Noton K Dutta; Michael L Pinn; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 5.  Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action.

Authors:  Leonard Amaral; Miguel Viveiros
Journal:  Antibiotics (Basel)       Date:  2017-01-14

Review 6.  The New Frontier of Host-Directed Therapies for Mycobacterium avium Complex.

Authors:  Nathan P Crilly; Samuel K Ayeh; Petros C Karakousis
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

Review 7.  Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis.

Authors:  Erik J Hasenoehrl; Thomas J Wiggins; Michael Berney
Journal:  Front Cell Infect Microbiol       Date:  2021-01-11       Impact factor: 5.293

Review 8.  Something Old, Something New: Ion Channel Blockers as Potential Anti-Tuberculosis Agents.

Authors:  Steven C Mitini-Nkhoma; Elizabeth T Chimbayo; David T Mzinza; David V Mhango; Aaron P Chirambo; Christine Mandalasi; Agness E Lakudzala; Dumizulu L Tembo; Kondwani C Jambo; Henry C Mwandumba
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.